Abstract

Drug targeting is a progressive area of research with folate receptor alpha (FRα) receiving significant attention as a biological marker in cancer drug delivery. The binding affinity of folic acid (FA) to the FRα active site provides a basis for recognition of FRα. In this study, FA was conjugated to beta-cyclodextrin (βCD) and subjected to in silico analysis (molecular docking and molecular dynamics (MD) simulation (100 ns)) to investigate the affinity and stability for the conjugated system compared to unconjugated and apo systems (ligand free). Docking studies revealed that the conjugated FA bound into the active site of FRα with a docking score (free binding energy < −15 kcal/mol), with a similar binding pose to that of unconjugated FA. Subsequent analyses from molecular dynamics (MD) simulations, root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (Rg) demonstrated that FA and FA–βCDs created more dynamically stable systems with FRα than the apo-FRα system. All systems reached equilibrium with stable RMSD values ranging from 1.9–2.4 Å and the average residual fluctuation values of the FRα backbone atoms for all residues (except for terminal residues ARG8, THR9, THR214, and LEU215) were less than 2.1 Å with a consistent Rg value of around 16.8 Å throughout the MD simulation time (0–100 ns). The conjugation with βCD improved the stability and decreased the mobility of all the residues (except residues 149–151) compared to FA–FRα and apo-FRα systems. Further analysis of H-bonds, binding free energy (MM-PBSA), and per residue decomposition energy revealed that besides APS81, residues HIS20, TRP102, HIS135, TRP138, TRP140, and TRP171 were shown to have more favourable energy contributions in the holo systems than in the apo-FRα system, and these residues might have a direct role in increasing the stability of holo systems.

Highlights

  • Chemotherapy remains as an important option in addition to other anticancer treatments including surgery and radiotherapy [1,2]

  • The results showed that folic acid (FA) and FA–βCD bound to the FRα active site via hydrogen bond (H-bond) with varying tendencies, and ASP81 remaining as the key amino acid in the H-bond interaction

  • Our findings suggest that FA–βCD is more dynamically stable than FA

Read more

Summary

Introduction

Chemotherapy remains as an important option in addition to other anticancer treatments including surgery and radiotherapy [1,2]. One of the most promising approaches to overcome adverse effects of anticancer drugs is utilizing targeted drug delivery system (TDDS) [1,3]. Conjugation of a drug delivery system with folic acid (FA) has been used to achieve active targeting [6,7] as FA can be recognized by FRα with high binding constants (Kd ∼ 1010 M−1) [5] This has led to the development of various folate-appended drug carriers such as liposomes [8,9,10], dendrimers [11,12,13] and micelles [14,15,16]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.